EU authorities accuse Teva of breaking competition rules
Teva accused of “pay for delay” deal with Cephalon.
X
EU authorities accuse Teva of breaking competition rules
https://pharmaphorum.com/news/eu-teva-competition-rules/
Teva
AstraZeneca CEO Soriot may stay after all
Soriot to host results announcement as usual
AZ CEO set to take charge at Teva – report
Report raises concerns about outcome of MYSTIC trial.
Celltrion and Teva set to take lead in US rituximab biosimilars
FDA decision due in Q1 2018
Alder shares slump despite migraine success
Investors concerned over strong placebo effect
Novartis files migraine drug with EMA
Erenumab could be first new treatment in a decade.
Teva plans migraine drug filing later this year
Blockbuster hopeful could launch next year if approved.
Teva on track to file migraine blockbuster
Phase 3 success for fremanezumab.
Data keeps Lilly in race for new migraine treatment
Company still in race to develop CGRP inhibitor for migraine.